Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of BridgeBio Pharma Inc (NASDAQ: BBIO) was $33.45 for the day, down -2.62% from the previous closing price of $34.35. In other words, the price has decreased by -$2.62 from its previous closing price. On the day, 8.93 million shares were traded.
Ratios:
Our analysis of BBIO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.67 and its Current Ratio is at 4.67.
On September 04, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $46.Piper Sandler initiated its Overweight rating on September 04, 2024, with a $46 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 25 ’25 when KUMAR HALDEA REVOCABLE TRUST U bought 300,000 shares for $36.25 per share.
BRIAN STEPHENSON bought 34,000 shares of BBIO for $1,232,500 on Feb 25 ’25. On Feb 19 ’25, another insider, STEPHENSON BRIAN C, who serves as the Secretary, Treasurer & CFO of the company, sold 4,148 shares for $36.16 each. As a result, the insider received 149,973 and left with 102,464 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 28.67.
Stock Price History:
Over the past 52 weeks, BBIO has reached a high of $39.47, while it has fallen to a 52-week low of $21.62. The 50-Day Moving Average of the stock is 4.52%, while the 200-Day Moving Average is calculated to be 20.57%.
Shares Statistics:
A total of 190.04M shares are outstanding, with a floating share count of 149.28M. Insiders hold about 21.51% of the company’s shares, while institutions hold 76.10% stake in the company.
